Misitatug blivedotin
Misitatug blivedotin (RC88) is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). Misitatug blivedotin binds to mesothelin and exhibits dose‐dependent antitumor activity. Misitatug blivedotin can be used for the research of ovarian cancer, non-squamous non-small-cell lung carcinoma, cervical cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
RC88 effectively blocks CA125 from binding to MSLN[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude mice (female; ages 4–5 weeks; implanted subcutaneously with 3 million OVCAR3‐MSLN‐3# or H292‐MSLN‐9C8 cells for a xenograft model)[3]
-
Dosage:0.7 mg/kg; 0.75 mg/kg; 1.5 mg/kg; 2.1 mg/kg; 3 mg/kg
-
Administration:i.v.; Q1W × 1 or Q1W × 3
-
Result:Had moderate activity at 0.75 mg/kg with single dosing, but tumor volume was less than the initial volume of tumors treated at 2.1 mg/kg until 11 days after dosing.
Significantly reduced the tumors 7 days after the first dosing at 1.5 and 3 mg/kg with multiple dosing.
Fully regressed tumors at 3 mg/kg for 10 days and at 1.5 mg/kg for 17 days, but the tumor continued to grow after three administrations at 0.75 mg/kg.
Chemical Information
-
SMILES
[Misitatug blivedotin]
-
Synonyms
RC88
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)